A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

Show other versions (1)

B A C K G R O U N D: Treatment for TB is lengthy and toxic, and new regimens are needed. M E T H O D S: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin (M) and 1500 mg pyrazinamide (Z) for 6 months (6Pa200MZ)...

Full description

Bibliographic Details
Main Authors: Amukoye, E. (Author), Balanag, V. (Author), Ban, A.Y.L (Author), Bateson, A.L.C (Author), Betteridge, M.C (Author), Brumskine, W. (Author), Caoili, J. (Author), Cevik, M. (Author), Chaisson, R.E (Author), Conradie, F. (Author), Crook, A.M (Author), Dawson, R. (Author), del Parigi, A. (Author), Diacon, A. (Author), Everitt, D.E (Author), Fabiane, S.M (Author), Gillespie, S.H (Author), Hunt, R. (Author), Ismail, A.I (Author), Lalloo, U. (Author), Lombard, L. (Author), Louw, C. (Author), Malahleha, M. (Author), McHugh, T.D (Author), Mendel, C.M (Author), Mhimbira, F. (Author), Moodliar, R.N (Author), Nduba, V. (Author), Nunn, A.J (Author), Sabi, I. (Author), Sebe, M.A (Author), Selepe, R.A.P (Author), Spigelman, M. (Author), Staples, S. (Author), Swindells, S. (Author), Tweed, C.D (Author), van Niekerk, C.H (Author), Variava, E. (Author), Wills, G.H (Author)
Format: Article
Language:English
Published: International Union Against Tuberculosis and Lung Disease 2021
Series:International Journal of Tuberculosis and Lung Disease
Subjects:
adult
aged
alanine aminotransferase
Antitubercular Agents
arthralgia
Article
aspartate aminotransferase
clinical protocol
combination drug therapy
controlled study
drug efficacy
Drug resistance
Drug Therapy, Combination
drug withdrawal
ethambutol
female
human
Humans
hypertransaminasemia
hyperuricemia
intention to treat analysis
isoniazid
K E Y W O R D S: tuberculosis
lung tuberculosis
major clinical study
male
moxifloxacin
Moxifloxacin
multicenter study
nitroimidazole derivative
Nitroimidazoles
open study
outcome assessment
patient selection
phase 3 clinical trial
pretomanid
pyrazinamide
Pyrazinamide
randomized controlled trial
relapse
rifampicin
TB treatment
TB-HIV
thorax radiography
treatment duration
treatment failure
treatment outcome
Treatment Outcome
treatment response
tuberculostatic agent
Online Access:View Fulltext in Publisher
View in Scopus

Internet

View Fulltext in Publisher
View in Scopus

Similar Items